

Regular Session, 2011

HOUSE BILL NO. 12

BY REPRESENTATIVES TEMPLET, ANDERS, ARNOLD, AUBERT, AUSTIN BADON, BOBBY BADON, BALDONE, BILLIOT, BROSSETT, HENRY BURNS, TIM BURNS, BURRELL, CARTER, CHAMPAGNE, CHANDLER, CHANEY, CONNICK, CORTEZ, CROMER, DANAHAY, DIXON, DOWNS, EDWARDS, ELLINGTON, FANNIN, FOIL, GEYMANN, GISCLAIR, GREENE, GUINN, HARDY, HARRISON, HAZEL, HENRY, HILL, HOFFMANN, HONORE, HOWARD, HUTTER, KATZ, LABRUZZO, LAMBERT, LANDRY, LEBAS, LIGI, LITTLE, MCVEA, MONTOUCET, MORENO, MORRIS, PEARSON, PONTI, POPE, PUGH, RICHARD, RICHARDSON, ROY, SCHRODER, SIMON, SMILEY, JANE SMITH, ST. GERMAIN, TALBOT, THIBAUT, TUCKER, WHITE, WILLIAMS, WILLMOTT, AND WOOTON AND SENATORS LAFLEUR, LONG, MARTINY, MILLS, MORRISH, QUINN, SHAW, SMITH, AND THOMPSON

Prefiled pursuant to Article III, Section 2(A)(4)(b)(i) of the Constitution of Louisiana.

1 AN ACT

2 To amend and reenact R.S. 40:964 (Schedule I)(E)(introductory paragraph), to enact R.S.  
3 40:964(Schedule I)(E)(8) and (9) and (F), and to repeal R.S. 40:964(Schedule  
4 I)(C)(32), relative to synthetic controlled dangerous substances; to add certain  
5 synthetic substances to Schedule I; and to provide for related matters.

6 Be it enacted by the Legislature of Louisiana:

7 Section 1. R.S. 40:964 (Schedule I)(E)(introductory paragraph) is hereby amended  
8 and reenacted and R.S. 40:964(Schedule I)(E)(8) and (9) and (F) are hereby enacted to read  
9 as follows:

10 §964. Composition of schedules

11 Schedules I, II, III, IV, and V shall, unless and until added to pursuant to R.S.  
12 40:962, consist of the following drugs or other substances, by whatever official  
13 name, common or usual name, chemical name, or brand name designated:

14 SCHEDULE I

15 \* \* \*

16 E. Stimulants. Unless specifically excepted, or contained within a  
17 pharmaceutical product approved by the United States Federal Food and Drug  
18 Administration, or unless listed in another schedule, any material, compound,

1 mixture, or preparation which contains any quantity of the following substances  
 2 having a stimulant effect on the central nervous system including its salts, isomers,  
 3 esters, or ethers and salts of isomers, esters, or ethers whenever the existence of such  
 4 salts, isomers, esters, or ethers and salts of isomers, esters, or ethers is possible  
 5 within the specific chemical designation:

6 \* \* \*

7 (8) Naphthylpyrovalerone whether or not further substituted in the naphthyl  
 8 ring to any extent with alkyl, alkoxy, alkylendioxy, haloalkyl or halide substituents,  
 9 whether or not further substituted in the naphthyl ring by one or more other univalent  
 10 substituents or whether or not further substituted in the carbon chain at the 3, 4, or  
 11 5 position with an alkyl substituent.

12 (9) 2-amino-1-phenyl-1-propanone (cathinone) or variation in any of the  
 13 following ways:

14 (i) By substitution in the phenyl ring to any extent with alkyl, alkoxy,  
 15 alkylendioxy, haloalkyl or halide substituents, whether or not further substituted in  
 16 the phenyl ring by one or more other univalent substituents.

17 (ii) By substitution at the 3-position with an alkyl substituent.

18 (iii) By substitution at the nitrogen atom with alkyl, dialkyl, or benzyl  
 19 groups, or by inclusion of the nitrogen atom in a cyclic structure.

20 F. Synthetic cannabinoids. Unless specifically excepted or unless listed in  
 21 another schedule, any material, compound, mixture, or preparation, which contains  
 22 any quantity of a synthetic cannabinoid found to be in any of the following chemical  
 23 groups, or any of those groups which contain any synthetic cannabinoid salts,  
 24 isomers, or salts of isomers, whenever the existence of such salts, isomers, or salts  
 25 of isomers is possible within the specific chemical designation, including all  
 26 synthetic cannabinoid chemical analogues in such groups:

27 (1) Naphthoylindoles whether or not substituted in the indole ring to any  
 28 extent or the naphthyl ring to any extent.

29 (2) Naphthylmethylindoles whether or not substituted in the indole ring to  
 30 any extent or the naphthyl ring to any extent.

1 (3) Naphthoypyrrroles whether or not substituted in the pyrrole ring to any  
 2 extent or the naphthyl ring to any extent.

3 (4) Naphthylmethylenes whether or not substituted in the indene ring to  
 4 any extent or the naphthyl ring to any extent.

5 (5) Phenylacetindoles whether or not substituted in the indole ring to any  
 6 extent or the phenyl ring to any extent.

7 (6) Cyclohexylphenols whether or not substituted in the cyclohexyl ring to  
 8 any extent or the phenyl ring to any extent.

9 (7) Dibenzopyrans whether or not substituted in the cyclohexyl ring to any  
 10 extent or the phenyl ring to any extent.

11 (8) Benzoylindoles whether or not substituted in the indole ring to any extent  
 12 or the phenyl ring to any extent.

13 \* \* \*

14 Section 2. R.S. 40:964(Schedule I)(C)(32) is hereby repealed in its entirety.

15 Section 3. This Act shall become effective on July 15, 2011; if vetoed by the  
 16 governor and subsequently approved by the legislature, this Act shall become effective on  
 17 July 15, 2011, or on the day following such approval by the legislature, whichever is later.

\_\_\_\_\_  
 SPEAKER OF THE HOUSE OF REPRESENTATIVES

\_\_\_\_\_  
 PRESIDENT OF THE SENATE

\_\_\_\_\_  
 GOVERNOR OF THE STATE OF LOUISIANA

APPROVED: \_\_\_\_\_